# Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

> **NCT00702819** · PHASE1 · TERMINATED · sponsor: **Vision Research Foundation** · enrollment: 2 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00702819
- **Lead sponsor:** Vision Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low enrollment due to the stringent enrollment criteria. Unable to answer study questions
- **Last updated:** 2010-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702819, "Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00702819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*